>>gsk had their own orexin in development but never got anywhere with it, so maybe that's why they were interested.<<
rkrw:
That would be GSK649868. How did you know (prior to this deal) that GSK "never got anywhere" with GSK649868? Are you simply going by the lack of clinical progress as measued by clinicaltrials.gov?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.